NYSEAMERICAN:OGEN - Oragenics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.62 +0.01 (+1.64 %)
(As of 03/24/2019 01:25 PM ET)
Previous Close$0.62
Today's Range$0.61 - $0.63
52-Week Range$0.38 - $3.74
Volume2.17 million shs
Average Volume1.47 million shs
Market Capitalization$18.25 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

Receive OGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OGEN
CUSIPN/A
Phone+1-813-2867900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$18.25 million
Next Earnings Date3/29/2019 (Estimated)
OptionableNot Optionable

Oragenics (NYSEAMERICAN:OGEN) Frequently Asked Questions

What is Oragenics' stock symbol?

Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN."

When did Oragenics' stock split? How did Oragenics' stock split work?

Oragenics shares reverse split on Monday, January 22nd 2018. The 1-10 reverse split was announced on Monday, January 8th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Oragenics stock prior to the reverse split would have 10 shares after the split.

How were Oragenics' earnings last quarter?

Oragenics Inc (NYSEAMERICAN:OGEN) announced its quarterly earnings data on Tuesday, November, 13th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.13. View Oragenics' Earnings History.

When is Oragenics' next earnings date?

Oragenics is scheduled to release their next quarterly earnings announcement on Friday, March 29th 2019. View Earnings Estimates for Oragenics.

Has Oragenics been receiving favorable news coverage?

Press coverage about OGEN stock has been trending positive this week, according to InfoTrie. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Oragenics earned a news sentiment score of 2.1 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days.

Are investors shorting Oragenics?

Oragenics saw a increase in short interest in the month of February. As of February 28th, there was short interest totalling 1,661,858 shares, an increase of 0.2% from the February 15th total of 1,657,882 shares. Based on an average trading volume of 795,349 shares, the short-interest ratio is currently 2.1 days. Approximately 6.5% of the company's shares are sold short. View Oragenics' Current Options Chain.

Who are some of Oragenics' key competitors?

What other stocks do shareholders of Oragenics own?

Who are Oragenics' key executives?

Oragenics' management team includes the folowing people:
  • Dr. Alan F. Joslyn, Pres, CEO & Director (Age 60)
  • Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 63)
  • Dr. Martin Handfield, Sr. VP of Discovery Research (Age 48)
  • Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant

Who are Oragenics' major shareholders?

Oragenics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.40%), Virtu Financial LLC (0.47%) and Barclays PLC (0.46%). View Institutional Ownership Trends for Oragenics.

Which major investors are buying Oragenics stock?

OGEN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Virtu Financial LLC and Barclays PLC. View Insider Buying and Selling for Oragenics.

How do I buy shares of Oragenics?

Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oragenics' stock price today?

One share of OGEN stock can currently be purchased for approximately $0.62.

How big of a company is Oragenics?

Oragenics has a market capitalization of $18.25 million.

What is Oragenics' official website?

The official website for Oragenics is http://www.oragenics.com.

How can I contact Oragenics?

Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The biotechnology company can be reached via phone at +1-813-2867900.


MarketBeat Community Rating for Oragenics (NYSEAMERICAN OGEN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  62 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  126
MarketBeat's community ratings are surveys of what our community members think about Oragenics and other stocks. Vote "Outperform" if you believe OGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel